CN115463172B - Traditional Chinese medicine composition for treating digestive tract mucous membrane injury - Google Patents
Traditional Chinese medicine composition for treating digestive tract mucous membrane injury Download PDFInfo
- Publication number
- CN115463172B CN115463172B CN202211156848.4A CN202211156848A CN115463172B CN 115463172 B CN115463172 B CN 115463172B CN 202211156848 A CN202211156848 A CN 202211156848A CN 115463172 B CN115463172 B CN 115463172B
- Authority
- CN
- China
- Prior art keywords
- parts
- white
- mucous membrane
- chinese
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 81
- 210000004400 mucous membrane Anatomy 0.000 title claims abstract description 36
- 230000006378 damage Effects 0.000 title claims abstract description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 208000027418 Wounds and injury Diseases 0.000 title abstract description 15
- 208000014674 injury Diseases 0.000 title abstract description 15
- 208000025865 Ulcer Diseases 0.000 claims abstract description 48
- 231100000397 ulcer Toxicity 0.000 claims abstract description 48
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 22
- 235000006533 astragalus Nutrition 0.000 claims abstract description 22
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 22
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 20
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000011787 zinc oxide Substances 0.000 claims abstract description 20
- 235000014692 zinc oxide Nutrition 0.000 claims abstract description 20
- 244000048199 Hibiscus mutabilis Species 0.000 claims abstract description 19
- 241000233805 Phoenix Species 0.000 claims abstract description 9
- 210000004379 membrane Anatomy 0.000 claims abstract description 9
- 239000012528 membrane Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 70
- 229940079593 drug Drugs 0.000 claims description 45
- 238000002156 mixing Methods 0.000 claims description 27
- 239000000843 powder Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000012141 concentrate Substances 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- 229940041678 oral spray Drugs 0.000 claims description 12
- 239000000668 oral spray Substances 0.000 claims description 12
- 241001412225 Firmiana simplex Species 0.000 claims description 11
- 239000009636 Huang Qi Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 8
- 239000000829 suppository Substances 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 6
- -1 polyoxyethylene stearate Polymers 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 41
- 235000005206 Hibiscus Nutrition 0.000 abstract description 16
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 abstract description 16
- 244000284380 Hibiscus rosa sinensis Species 0.000 abstract description 16
- 235000003973 Hibiscus mutabilis Nutrition 0.000 abstract description 15
- 230000003628 erosive effect Effects 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 230000035876 healing Effects 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 27
- 101150086731 ges-1 gene Proteins 0.000 description 19
- 235000014347 soups Nutrition 0.000 description 19
- 238000000034 method Methods 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- 230000004663 cell proliferation Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 9
- 210000002919 epithelial cell Anatomy 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 208000002399 aphthous stomatitis Diseases 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 235000021391 short chain fatty acids Nutrition 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000000306 recurrent effect Effects 0.000 description 5
- 206010061297 Mucosal erosion Diseases 0.000 description 4
- 208000007117 Oral Ulcer Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 3
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 235000008081 Rheum officinale Nutrition 0.000 description 3
- 240000001745 Rheum palmatum Species 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RIXNFYQZWDGQAE-DFHVBEEKSA-N (4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-acetyloxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C([C@H]1C2=CC[C@H]34)C(C)(C)CC[C@]1(C(O)=O)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C RIXNFYQZWDGQAE-DFHVBEEKSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 230000007730 Akt signaling Effects 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 101100174785 Bacillus subtilis (strain 168) ganS gene Proteins 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 230000022963 DNA damage response, signal transduction by p53 class mediator Effects 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 102000000341 S-Phase Kinase-Associated Proteins Human genes 0.000 description 2
- 108010055623 S-Phase Kinase-Associated Proteins Proteins 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000020670 canker sore Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000015864 chronic erosive gastritis Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 101150108006 cycB gene Proteins 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 238000010201 enrichment analysis Methods 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 239000008876 liujunzi Substances 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- KAZSKMJFUPEHHW-UHFFFAOYSA-N (2E)-3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hdyroxyphenyl)-2-propen-1-one Natural products COC1=CC(O)=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- DJTOLSNIKJIDFF-LOVVWNRFSA-N 5alpha-Androstan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 DJTOLSNIKJIDFF-LOVVWNRFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 108010031677 Anaphase-Promoting Complex-Cyclosome Proteins 0.000 description 1
- 102000005446 Anaphase-Promoting Complex-Cyclosome Human genes 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 101150078602 BUB3 gene Proteins 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 101100005729 Caenorhabditis elegans cdc-14 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 description 1
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 1
- 241000223782 Ciliophora Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 101100411547 Danio rerio rad21a gene Proteins 0.000 description 1
- 101100193652 Dictyostelium discoideum rapA gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100036254 E3 SUMO-protein ligase PIAS2 Human genes 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 102100038720 Histone deacetylase 9 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000723543 Homo sapiens 14-3-3 protein theta Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101001074629 Homo sapiens E3 SUMO-protein ligase PIAS2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- IUCVKTHEUWACFB-UHFFFAOYSA-N Licochalcone A Natural products COC1=CC=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 IUCVKTHEUWACFB-UHFFFAOYSA-N 0.000 description 1
- KAZSKMJFUPEHHW-DHZHZOJOSA-N Licochalcone A Chemical compound COC1=CC(O)=C(C(C)(C)C=C)C=C1\C=C\C(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-DHZHZOJOSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010024572 Lip ulceration Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 101100273648 Mus musculus Ccna2 gene Proteins 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 101100042789 Schizosaccharomyces pombe (strain 972 / ATCC 24843) psm1 gene Proteins 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- MXZRMHIULZDAKC-UHFFFAOYSA-L ammonium magnesium phosphate Chemical compound [NH4+].[Mg+2].[O-]P([O-])([O-])=O MXZRMHIULZDAKC-UHFFFAOYSA-L 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- FOFYPMPFTYORPL-UHFFFAOYSA-N azanium;2,8-dioxo-7,9-dihydro-3h-purin-6-olate Chemical compound N.N1C(=O)NC(=O)C2=C1NC(=O)N2 FOFYPMPFTYORPL-UHFFFAOYSA-N 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 101150024637 cycH gene Proteins 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 101150093523 dbf4 gene Proteins 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000011318 facial edema Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 235000002324 isoflavanes Nutrition 0.000 description 1
- 235000008718 isoliquiritigenin Nutrition 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000004147 pyrimidine metabolism Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 101150114778 rad21 gene Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000009705 sanhuang Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 101150056532 terf2ip gene Proteins 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 150000007971 urates Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000010151 yanghe Substances 0.000 description 1
- 239000009310 zuojin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating digestive tract mucous membrane injury, which comprises the following raw materials in parts by weight: 25-35 parts of astragalus membranaceus, 16-23 parts of cotton rose hibiscus leaves, 12-18 parts of glossy privet fruits, 8-12 parts of Chinese yolks, 8-12 parts of phoenix membranes and 5-8 parts of Chinese white. The invention is safe and effective, treats both principal and secondary aspect of disease, and has obvious curative effect on digestive tract mucous membrane erosion and ulcer.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine production, in particular to a traditional Chinese medicine composition for treating digestive tract mucous membrane injury.
Background
The digestive tract mucous membrane injury refers to tissue injury including oral mucous membrane, esophagus, stomach, duodenum, large and small intestinal tract erosion, ulcer mucous membrane lesion and the like. Clinical medicine has studied pathological mechanism deeply from many aspects, and developed medicines such as membrane protectant, proton pump inhibitor, anti-infection and immunosuppressant, but the quality of mucous membrane healing, long-term recurrence rate, autoimmune function improvement, helicobacter pylori reinfection, etc. are still difficult to achieve, and part of medicines have long-term cancerogenic risk, cannot be used for a long time, have no specificity and cure, and have repeated illness state.
The traditional Chinese medicine decoction pieces are introduced into the literature such as 'observation of the effect of treating gastric ulcer' (volume 13, 2A (67-68 pages) of clinical reasonable medication), 'research of the curative effect of Chinese medicine Xiangshan Liujunzi decoction on gastric ulcer' (volume 12, 21, 205-206 pages of Chinese modern medicine application, 2018) and 'clinical diagnosis and treatment of gastroenterology special diseases' (pages 27-72 2005 of Beijing people health press), and the traditional Chinese medicine for researching mucous membrane injury is mainly developed at present: the compound traditional Chinese medicines comprise radix bupleuri, liver soothing powder, dajian Zhongtang, fu Zizhong Tang, sanhuang Xiexin Tang, huangqi Jianzhong Tang, kangfu liquor, qi regulating and stomach regulating decoction, qingzhong Tang, five-flavor sterilizing decoction, xiangsha Liujunzi Tang, stomach nourishing particles, chai Shaoyi stomach decoction, liver soothing and spleen strengthening decoction, stomach nourishing decoction, zuojin Wan, yang He Tang, stomach invigorating and ulcer curing tablet and the like.
For recurrent oral ulcer, the common western medicine is thalidomide, the medicine has quick response, but can only treat the symptoms, cannot treat the root cause, is easy to relapse after stopping the medicine, has great side effects, especially has serious teratogenicity on a fetus, also causes infertility and common adverse reactions such as dry mouth and nose mucous membrane, listlessness, somnolence, dizziness, rash, constipation, nausea, abdominal pain, facial edema, and the like, and can possibly cause polyneuritis, anaphylactic reaction and the like.
The existing treatment methods cannot cure, can only provide temporary symptom relief, and can be accompanied by serious side effects. The health problem is still lacking in effective, safe and long-term adverse reaction free drugs. There is an urgent need to find new natural complexes with strong activity and acceptable safety, promoting rapid healing of erosion or ulcers, preventing recurrent canceration. The traditional Chinese medicine has been practiced and developed for thousands of years, and the composition is distinguished under the guidance of the traditional Chinese medicine theory, and is strictly processed, so that the comprehensive effects of multiple targets, multiple ways and multiple links can be exerted. The method has the advantages of improving clinical symptoms of lesions, improving the maturity of regenerated mucous membrane, improving healing quality, reducing long-term recurrence rate and the like, and is an effective and feasible treatment idea.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating digestive tract mucous membrane injury, which is safe and effective, treats both principal and secondary aspect of disease, and has obvious curative effect on digestive tract erosion and ulcer.
The technical scheme adopted for solving the technical problems is as follows:
a traditional Chinese medicine composition for treating digestive tract mucous membrane injury comprises the following raw materials in parts by weight: 25-35 parts of astragalus membranaceus, 16-23 parts of cotton rose hibiscus leaves, 12-18 parts of glossy privet fruits, 8-12 parts of Chinese yolks, 8-12 parts of phoenix membranes and 5-8 parts of Chinese white.
Preferably, the adhesive comprises the following raw materials in parts by weight: 30 parts of astragalus membranaceus, 20 parts of cotton rose hibiscus leaves, 15 parts of glossy privet fruits, 10 parts of human Zhonghuang, 10 parts of phoenix tree skin and 6 parts of human white.
No research report on the traditional Chinese medicine composition composed of 6 medicines is found in the literature. In human body experiments, clinical symptoms and mucous membrane tissue healing can be seen to have a good clinical effect, and in-vitro basic experiments can be seen to be that the ulcer healing soup can promote proliferation of humanized gastric mucous membrane cells. Experiments show that there are significant differences between total 312 gene expressions and control groups, 233 genes are significantly up-regulated, 79 genes are significantly down-regulated (the difference multiple is more than or equal to 2, and P is less than 0.05), and 312 difference genes are enriched on 210 signal paths in the KEGG database. These pathways can be grouped into three major aspects, namely, cell, metabolic, and cancer. Wherein the metabolic-related pathway comprises cell-related pathways including cell adhesion molecules Cell Adhesion Molecules (CAMs), rap1 signaling pathway, JAK-STAT, mitogen-activated protein kinase signaling pathway (MAPK signaling pathway), cytoplasmic signaling pathway (Cytosolic DNA-sensing pathway), modulation of stem cell multipotent signaling pathway (Signaling pathways regulating pluripotency of stem cells), epithelial cell signaling in Hp infection (Epithelial cell signaling in Helicobacter pylori infection), and the like. Metabolic pathway (Glycerophospholipid metabolism), galactose metabolism (Galactose metabolism), PPAR (Pyrimidine metabolism), fructose and mannose metabolism (Fructose and mannose metabolism), and the like. Cancer-associated pathways include the PI3K-Akt signaling pathway (PI 3K-Akt signaling pathway), the p53 signaling pathway (p 53 signaling pathway), and the like. The channel enrichment analysis shows that the ulcer healing soup influences the gastric mucosa epithelial function by regulating the signal transmission process of the above channels. Therefore, the effect of the invention is focused on regulating immunity, mobilizing self-repairing capability, and simultaneously carrying out local repairing and promoting mucous membrane healing. The genes which indicate the differential expression with the cell proliferation participate in the growth and development of the cells, interact with the invention, and promote and accelerate the occurrence of clinical erosion and ulcer healing through specific channels. In addition, total extracts containing 823 active ingredients such as the component of the compound is obtained through extraction and mass spectrometry analysis, and the compound can inhibit signal paths in the processes of inflammation and tumor generation and development, play an anti-inflammatory and anti-tumor role, and the chemical components of the compound such as smooth muscle and blood vessels are expanded, microcirculation disturbance is improved, local blood flow is increased and the like according to the document description of the influence of different doses of the component of the compound on severe acute pancreatitis of rats (pages 14-19 of 3 rd of volume 20 of journal of microcirculation in 2010). According to the description of the Chinese medicine dictionary, the pharmacological study of single medicine shows that the Chinese rhubarb is a processed product of licorice and faeces juice, and mainly contains glycyrrhizin, isoliquiritigenin, glycyrrhizic acid, glycyrrhetinic acid and licochalcone A. White in humans is a precipitate produced by the long-term standing of human urine due to the change of the pH value in urine. Uric acid, urates, calcium sulfate and calcium hydrophosphate are precipitated in an acidic environment, and several amino acids are fashionable; precipitated in alkaline environment are calcium carbonate, magnesium ammonium phosphate, calcium phosphate, magnesium phosphate, uric acid ammonia, calcium oxalate, etc. The folium Hibisci Mutabilis contains flavonoid glycoside, phenols, amino acids, tannins and reducing sugar. The membrana Follicularis ovi contains keratin as main component and small amount of mucin fiber sandwiched therein. Astragalus contains sucrose, glucuronic acid, mucin, several amino acids, picrin, choline, betaine, folic acid, 2',4' -dihydroxy-5, 6-dimethoxy isoflavane and androstanol. The saponification product of the inner Mongolian astragalus lipid is separated into linoleic acid and linolenic acid, and the non-saponification part is beta-sitosterol. Fructus Ligustri Lucidi fruit contains oleanolic acid, mannitol, glucose, palmitic acid, stearic acid, oleic acid, linoleic acid, pericarp contains oleanolic acid, acetyl oleanolic acid, androstearic acid, seed contains fatty oil 14.9%, palmitic acid and stearic acid in oil are 19.5%, oleic acid and linolenic acid are 80.5%.
In the invention, astragalus root is sweet and warm, and has the effects of expelling toxin and promoting tissue regeneration, inducing diuresis and relieving swelling, ascending yang and sinking, and tonifying middle-jiao, and is a monarch drug for mainly treating carbuncle without ulcer or chronic ulcer without healing; the Chinese medicinal composition has effects of clearing heat, cooling blood, and removing toxic substances, and can be used for treating pyocutaneous disease; the Chinese medicinal composition is mainly used for treating aphtha of the mouth and tongue by clearing heat, reducing fire and removing blood stasis, and is used as ministerial drug; the hibiscus leaves are used for cooling blood, detoxifying, detumescence and relieving pain, and are mainly used for treating carbuncle and swelling; the membrana Follicularis ovi nourishes yin and treats the ulcer with unhealing; glossy privet fruit, fructus Ligustri Lucidi, has effects of nourishing liver and kidney, and regulating immunity, and is used as adjuvant drug. Mild medicine property, addresses both the symptoms and root causes, promotes the repair of mucous membrane, accelerates mucous membrane healing, and eliminates the root cause of recurrence.
The 6 components of the invention are reasonably compatible and cooperatively play roles, can effectively repair the damage of the mucous membrane of the digestive tract, can regulate immunity and mobilize the repair capability of the mucous membrane, can repair the mucous membrane locally, can promote the healing of the mucous membrane, is safe and effective, can treat both the symptoms and root causes, and can change the microbial flora at the lesion, promote the reproduction of beneficial bacteria and inhibit the growth of harmful bacteria, thereby repairing the mucous membrane from the microecological environment.
The invention has obvious curative effect on mucosal lesions such as oral mucosa, esophagus, stomach, duodenum, large intestine, small intestine, rectum and the like, and ulcers and the like, and can also be used for cervical erosion lesions. And is also effective in preventing and treating chronic atrophic gastritis. The invention is summarized in long-term clinical practice according to the guidance of the traditional Chinese medicine theory, and is designed aiming at clinical lesion and lesion of mucous membrane of digestive tract. Different from the prior single drug or a certain active ingredient, the drug resistance can be reduced in long term in clinic, and the preparation is more fit for the clinical practice of traditional Chinese medicine, and has higher application value. Because the traditional method has no specific medicine for modern diseases such as digestive tract mucous membrane injury, the accurate treatment is slightly insufficient. The invention aims at the mucous membrane injury establishment, and clinical observation shows that the near-term and long-term effects are satisfactory.
Preferably, the Chinese medicinal composition is prepared into tablets, capsules, water aquas, suppositories or powder.
The crude drug content of the sore-healing oral spray is 2-3g/mL, and the crude drug consists of the following components in parts by weight: 25-35 parts of astragalus membranaceus, 16-23 parts of cotton rose hibiscus leaves, 12-18 parts of glossy privet fruits, 8-12 parts of Chinese yolks, 8-12 parts of phoenix membranes and 5-8 parts of Chinese white.
Preferably, the preparation method comprises the following steps:
(1) Mixing radix astragali, folium Hibisci Mutabilis, fructus Ligustri Lucidi, human middle-yellow and membrana Follicularis ovi according to formula, soaking in water for 1-2 hr according to the ratio of 1g of medicinal materials to 10-15mL of water, decocting for 3 times to obtain decoction, filtering, concentrating under reduced pressure to obtain primary concentrate containing crude drug 1-1.5g/mL, cooling, adding 95% ethanol of 3 times volume into the primary concentrate, standing overnight, sucking supernatant, recovering ethanol, and concentrating to obtain secondary concentrate containing crude drug 2-3g/m L; adding 95% ethanol 3 times of the volume of the secondary concentrated solution, standing overnight, sucking supernatant, recovering ethanol, and concentrating to obtain tertiary concentrated solution containing crude drug 4-6 g/mL;
weighing Chinese white according to the formula amount, mixing and extracting Chinese white according to the proportion of 1g medicinal material and 8-10mL70-80% ethanol, extracting for 2-3 times at 50-60 ℃ for 1-2 hours each time, filtering, and mixing the extracting solutions;
(2) Filtering the concentrated solution for three times, mixing with the white extractive solution to obtain oral spray with crude drug content of 2-3g/mL for treating ulcer, and packaging.
The suppository for curing ulcer is prepared by mixing 10-20% of medicinal powder and 80-90% of polyoxyethylene stearate according to weight percentage, wherein the medicinal powder comprises the following components in parts by weight: 25-35 parts of astragalus membranaceus, 16-23 parts of cotton rose hibiscus leaves, 12-18 parts of glossy privet fruits, 8-12 parts of Chinese yolks, 8-12 parts of phoenix membranes and 5-8 parts of Chinese white.
Preferably, the medicinal powder is prepared by mixing radix astragali, folium Hibisci Mutabilis, fructus Ligustri Lucidi, homo, membrana Follicularis ovi and homo uniformly, micronizing, and sieving.
The beneficial effects of the invention are as follows: the invention mutually proves that the traditional Chinese medicine compound has obvious curative effect in preventing and treating the damage of the digestive tract mucous membrane through clinical tests and cytology and genomics experiments, preliminarily discusses the mechanism of the component for preventing and treating the damage of the digestive tract mucous membrane, is favorable for developing further deep research on the traditional Chinese medicine compound, lays a foundation for expanding the clinical application range of the ulcer healing soup and promoting the development and utilization of the ulcer healing soup, and finds a further promising substance in searching good medicine ways for preventing and treating the damage of the digestive tract mucous membrane.
Drawings
Fig. 1: macroscopic observation of ulcer healing decoction for treating chronic canker sore patients, and the mucosa (lower lip ulcer) before and after treatment shows that: before 1C intervention, after 1D intervention, chronic erosive gastritis is under the scope and pathological manifestations: 1E gastric mass multiple erosive foci, 1F pathology (gastric mass erosive HP positive). The following is indicated: the ulcer healing soup has good repairing effect on clinical gastrointestinal mucosa injury.
FIG. 2 is a graph showing the relationship between the concentration of the ulcer healing soup and the proliferation activity of cells; the ulcer healing soup has the strongest promoting effect on the proliferation activity of gastric mucosa epithelial cells when the administration concentration is 80 mug/mL; the abscissa indicates the administration concentration of Yuyang decoction, and the ordinate indicates the cell proliferation activity.
FIG. 3 is a graph showing the relationship between the administration time of the Yuyang decoction and the proliferation activity of cells, wherein the Yuyang decoction Shang Nongdu has the best effect of promoting the proliferation activity of gastric mucosal epithelial cells at 80 mug/mL for 24 hours; the abscissa indicates the time of administration of the Yuyang decoction, and the ordinate indicates the proliferation activity of the cells.
FIG. 4 is an in vitro human gastric mucosal epithelial cell (GES-1) cell gene expression differential experiment: 312 differential expression genes related to cell proliferation, wherein 233 up-regulation and 79 down-regulation are enriched in 210 signal paths. Group1: control Group, group2: experimental drug groups. Description: the ulcer healing soup has a large effect on GES-1 cells, and influences the functions of gastric mucosa epithelium by regulating the signal transmission process of various channels.
Detailed Description
The technical scheme of the invention is further specifically described by the following specific examples.
In the present invention, the materials and equipment used are commercially available or commonly used in the art, unless otherwise specified. The methods in the following examples are conventional in the art unless otherwise specified.
Example 1:
a traditional Chinese medicine composition for treating digestive tract mucous membrane injury comprises the following raw materials in parts by weight: 25 parts of astragalus membranaceus, 23 parts of cotton rose hibiscus leaves, 18 parts of glossy privet fruit, 8 parts of human Zhonghuang, 8 parts of phoenix tree skin and 8 parts of human Bai.
Example 2:
a traditional Chinese medicine composition for treating digestive tract mucous membrane injury comprises the following raw materials in parts by weight: 35 parts of astragalus membranaceus, 16 parts of cotton rose hibiscus leaves, 12 parts of glossy privet fruits, 12 parts of human Zhonghuang, 12 parts of phoenix tree skin and 5 parts of human white.
Example 3:
a traditional Chinese medicine composition for treating digestive tract mucous membrane injury comprises the following raw materials in parts by weight: 30 parts of astragalus membranaceus, 20 parts of cotton rose hibiscus leaves, 15 parts of glossy privet fruits, 10 parts of human Zhonghuang, 10 parts of phoenix tree skin and 6 parts of human white.
Example 4:
the crude drug content of the sore-healing oral spray is 2g/mL, and the crude drug consists of the following components in parts by weight: 25 parts of astragalus membranaceus, 23 parts of cotton rose hibiscus leaves, 18 parts of glossy privet fruit, 8 parts of human Zhonghuang, 8 parts of phoenix tree skin and 8 parts of human Bai.
The preparation method comprises the following steps:
(1) Mixing radix astragali, folium Hibisci Mutabilis, fructus Ligustri Lucidi, human middle-yellow and membrana Follicularis ovi according to formula, soaking in water for 1 hr according to the ratio of 1g of medicinal materials to 10mL of water, decocting for 3 times (first decoction for 1.5 hr, second decoction for 1 hr, third decoction for 40min, second and third decoction adding water amount of 1g of medicinal materials to 5 mL) to obtain decoction, filtering, concentrating under reduced pressure to obtain primary concentrate containing crude drug 1g/mL, cooling, adding 95% ethanol of 3 times volume of the primary concentrate, standing overnight, absorbing supernatant, recovering ethanol and concentrating to obtain secondary concentrate containing crude drug 2g/m L; adding 95% ethanol 3 times of the volume of the secondary concentrated solution, standing overnight, sucking supernatant, recovering ethanol, and concentrating to obtain tertiary concentrated solution containing crude drug 4 g/mL;
weighing Chinese white according to the formula amount, mixing and extracting Chinese white according to the proportion of 1g of medicinal materials and 8mL of 80% ethanol, extracting for 3 times at 50 ℃ for 1 hour each time, filtering, and combining the extracting solutions;
(2) Filtering the concentrated solution for three times, mixing with the white extractive solution to obtain oral spray with crude drug content of 2g/mL for treating ulcer, and packaging.
Example 5:
the crude drug content of the sore-healing oral spray is 3g/mL, and the crude drug consists of the following components in parts by weight: 35 parts of astragalus membranaceus, 16 parts of cotton rose hibiscus leaves, 12 parts of glossy privet fruits, 12 parts of human Zhonghuang, 12 parts of phoenix tree skin and 5 parts of human white.
The preparation method comprises the following steps:
(1) Mixing radix astragali, folium Hibisci Mutabilis, fructus Ligustri Lucidi, human middle-yellow and membrana Follicularis ovi according to formula, soaking in water for 2 hr according to the ratio of 5mL water added into 1g medicinal material, decocting for 3 times (first decoction for 1.5 hr, second decoction for 1 hr, third decoction for 40min, second and third decoction water addition amount is 1g medicinal material and 5 mL), filtering, concentrating under reduced pressure to obtain primary concentrate containing crude drug 1.5g/mL, cooling, adding 95% ethanol of 3 times volume into the primary concentrate, standing overnight, absorbing supernatant, recovering ethanol and concentrating to obtain secondary concentrate containing crude drug 3g/m L; adding 95% ethanol 3 times of the volume of the secondary concentrated solution, standing overnight, sucking supernatant, recovering ethanol, and concentrating to obtain tertiary concentrated solution containing crude drug 6 g/mL;
weighing Chinese white according to the formula amount, mixing and extracting Chinese white according to the proportion of 1g of medicinal materials and 10mL of 75% ethanol, extracting for 2 times at 60 ℃ for 2 hours each time, filtering, and combining the extracting solutions;
(2) Filtering the concentrated solution for three times, mixing with the white extractive solution to obtain oral spray with crude drug content of 3g/mL for treating ulcer, and packaging.
Example 6:
the crude drug content of the sore-healing oral spray is 2g/mL, and the crude drug consists of the following components in parts by weight: 30 parts of astragalus membranaceus, 20 parts of cotton rose hibiscus leaves, 15 parts of glossy privet fruits, 10 parts of human Zhonghuang, 10 parts of phoenix tree skin and 6 parts of human white.
The preparation method comprises the following steps:
(1) Mixing radix astragali, folium Hibisci Mutabilis, fructus Ligustri Lucidi, human middle-yellow and membrana Follicularis ovi according to formula, soaking in water for 1 hr according to the ratio of 1g of medicinal materials to 10mL of water, decocting for 3 times (first decoction for 1.5 hr, second decoction for 1 hr, third decoction for 40min, second and third decoction adding water amount of 1g of medicinal materials to 5 mL) to obtain decoction, filtering, concentrating under reduced pressure to obtain primary concentrate containing crude drug 1g/mL, cooling, adding 95% ethanol of 3 times volume of the primary concentrate, standing overnight, absorbing supernatant, recovering ethanol and concentrating to obtain secondary concentrate containing crude drug 2g/m L; adding 95% ethanol 3 times of the volume of the secondary concentrated solution, standing overnight, sucking supernatant, recovering ethanol, and concentrating to obtain tertiary concentrated solution containing crude drug 4 g/mL;
weighing Chinese white according to the formula amount, mixing and extracting Chinese white according to the proportion of 1g of medicinal materials and 8mL of 70% ethanol, extracting for 3 times at 50 ℃ for 1 hour each time, filtering, and combining the extracting solutions;
(2) Filtering the concentrated solution for three times, mixing with the white extractive solution to obtain oral spray with crude drug content of 2g/mL for treating ulcer, and packaging.
Example 7:
the suppository for curing ulcer is prepared by mixing 10% of medicinal powder and 90% of polyoxyethylene stearate according to weight percentage, wherein the medicinal powder comprises the following components in parts by weight: 25 parts of astragalus membranaceus, 23 parts of cotton rose hibiscus leaves, 18 parts of glossy privet fruit, 8 parts of human Zhonghuang, 8 parts of phoenix tree skin and 8 parts of human Bai. The medicinal powder is prepared by mixing radix astragali, folium Hibisci Mutabilis, fructus Ligustri Lucidi, herba Origani, membrana Follicularis ovi and human white, micronizing, and sieving.
Example 8:
the suppository for curing ulcer is prepared by mixing 20% of medicinal powder and 80% of polyoxyethylene stearate according to weight percentage, wherein the medicinal powder comprises the following components in parts by weight: 35 parts of astragalus membranaceus, 16 parts of cotton rose hibiscus leaves, 12 parts of glossy privet fruits, 12 parts of human Zhonghuang, 12 parts of phoenix tree skin and 5 parts of human white. The medicinal powder is prepared by mixing radix astragali, folium Hibisci Mutabilis, fructus Ligustri Lucidi, herba Origani, membrana Follicularis ovi and human white, micronizing, and sieving.
Example 9:
the suppository for curing ulcer is prepared by mixing 15% of medicinal powder and 85% of polyoxyethylene stearate according to weight percentage, wherein the medicinal powder comprises the following components in parts by weight: 30 parts of astragalus membranaceus, 20 parts of cotton rose hibiscus leaves, 15 parts of glossy privet fruits, 10 parts of human Zhonghuang, 10 parts of phoenix tree skin and 6 parts of human white. The medicinal powder is prepared by mixing radix astragali, folium Hibisci Mutabilis, fructus Ligustri Lucidi, herba Origani, membrana Follicularis ovi and human white, micronizing, and sieving.
Test 1:
the subjects adopted in the study specifically comprise 30 cases of recurrent oral ulcer, 30 cases of gastric ulcer (comprising duodenal ulcer) and 100 cases of chronic erosive gastritis, and the subjects are taken into the population from 2016 month 04 to 2017 month 02, and the treatment is carried out for 1-6 months on the basis of the invention.
The preparation method comprises the steps of 30g of astragalus membranaceus, 20g of cotton rose hibiscus leaves, 15g of glossy privet fruits, 10g of Chinese rhubarb (fried), 10g of phoenix membrane and 6g of Chinese white (dried in a baking oven at 50 ℃ C. Of Chinese white and then crushed, sieved by a 20-mesh sieve, and swallowed for 6g each day for 2 times). Soaking the Chinese medicinal decoction pieces (without white powder) for 2 hr, heating to 100deg.C, decocting to obtain decoction for 2 times, pulverizing white powder, and taking the decoction to obtain white powder for 1 day for 2 times. The invention intervenes in clinical symptoms of canker sore lesions to obtain recovery, and the main and secondary symptoms are improved. Follow-up shows that the ulcer healing quality is good, and the long-term effect is remarkable (figure 1). The effective rate reaches 93 percent.
Test 2: experiments on proliferation and Gene expression of human gastric mucosal epithelial cells (GES-1)
2.1 methods of research
2.1.1 preparation of Compound traditional Chinese medicine
The medicines used in the research are prepared from decoction pieces (Zhejiang tung juntang Chinese herbal decoction pieces Co., ltd.) 10g, zhenzhong Huang, zhenzhong Bai 6g, furong leaf 20g, fenghuang 10g, astragalus membranaceus 30g and Ligustrum lucidum 15g; decocting for 2 times, fixing volume to 1000ml, packaging into 50ml centrifuge tube, freezing at-80 deg.C for overnight, cooling to-98deg.C in advance for half an hour, and drying in a freeze drying system for 48 hr to obtain dry powder (freeze dryer No. 2016714306, SP Scientific company, USA), packaging, and preserving at-20deg.C.
2.1.2 determination of reasonable drug concentration and time of action of GES-1
2.1.2.1 MTT colorimetric method for detecting influence of different concentrations on proliferation activity of GES-1 cells the GES-1 cell culture solution is added with the Yuyang decoction (obtained by adding water into 2.1.1 dry powder), and the drug concentration is 0 mug/mL, 10 mug/mL, 20 mug/mL, 40 mug/mL, 80 mug/mL, 160 mug/mL, 320 mug/mL, 640 mug/mL, 1280 mug/mL and 2560 mug/mL respectively. The MTT method is used for detecting the influence of the ulcer healing soup with different concentrations on the proliferation activity of the GES-1 cells, and the reasonable drug concentration of the ulcer healing soup in the GES-1 cell culture solution is determined according to the influence. The method comprises the following steps: cells were added in 96-well plates at 100. Mu.l/well (about 1X 10) 4 ) Each group had 5 duplicate wells. The above ulcer healing soup with different concentrations is added, and the blank control group is only added with culture solution and no ulcer healing soup. 37 ℃ 5% CO 2 After 48h incubation in an incubator with MTT for 4h incubation, 150. Mu.l of DMSO was added and shaken for 10min, and absorbance was measured at 570 nm.
2.1.2.2 effects of decoction for treating ulcer on GES-1 cell proliferation activity
GES-1 cells were subcultured with medium, and the cells were seeded in 5 96-well plates at 100ul per well (about 1X 10) 4 ) 6 multiple wells per group, 5% CO at 37 DEG C 2 After overnight culture in the incubator, the cells are acted at the ulcer healing soup concentration of 80 mug/mL, and the cells are continuously cultured and are divided into the following steps according to the ulcer healing soup acting time: 4 groups of 12h,24h,36h and 48 h. The blank control group is not added with the ulcer healing soup culture solution. After the drug action time is reached, the drug action is stopped, MTT is added for incubation for 4 hours, 150 μl of DMSO is added for shaking for 10 minutes, and the absorbance value is detected at the wavelength of 570 nm.
2.1.3 procedure for cell genome experiments:
2.1.3.1 genomic RNA extraction
Sample RNA was extracted using the TriZol method.
2.1.3.2RNA sequencing and analytical methods.
Detecting RNA of normal group, the invention intervenes in group sequencing, and uses DEGUST @ to perform the following procedureshttp://victorian- bioinformatics-consortium.github.io/degust/) Genes that significantly alter expression were screened.
Analysis of RNA sequencing results described how significantly altering expressed genes affected proliferation of GES-1 cells. Meanwhile, the curative effect mechanism of the compound traditional Chinese medicine for promoting cell proliferation is described from the aspect of molecular biology.
Results:
effect of Yuyang decoction on GES-1 cell proliferation Activity (FIG. 2)
TABLE 1 Effect of various concentrations of Yuyang decoction on GES-1 cell proliferation Activity
Note that: (1), (2), (3) P < 0.001vs.0.00. Mu.g/mL
Based on the above evidence, it can be determined that the optimal action concentration of the Yuyang decoction on GES-1 cells is 80 mug/mL. Therefore, the optimal acting time of the ulcer healing soup can be selected, and the concentration condition can be 80 mug/mL.
(II) effect of various action times of Yuyang decoction on GES-1 cell proliferation activity (FIG. 3)
TABLE 2 Effect of various incubation times of Yuyang decoction on GES-1 cell proliferation Activity
| 80.00(μg/mL) | |
| 1h | 1.015±0.031 |
| 2h | 1.016±0.020 |
| 4h | 1.054±0.037 |
| 6h | 1.074±0.065 |
| 12h | 1.160±0.059 |
| 24h | 1.325±0.034(1) |
| 36h | 1.306±0.026(2) |
| 48h | 1.147±0.038 |
| 0.00(μg/mL) | 1.000±0.023 |
Note that: (1) (2) P <0.05 vs.0.00. Mu.g/mL
The ulcer healing soup in tables 1 and 2 has no toxicity to GES-1 cell activity in the range of 0-24 h, and when the effect time of the ulcer healing soup reaches 36-48 h, the cell activity begins to decrease. Therefore, the effect of the Yuyang decoction on gene expression of GES-1 cells can be studied within the range of the concentration of 80.00 mug/mL and the action time of 24 hours.
GES-1 cell differential gene expression analysis
1. Sample collection and preparation
1. RNA extraction and detection: agilent 2100bioanalyzer: RNA integrity and total amount were accurately detected.
2. Library construction and quality inspection: the pool-forming starting RNA was total RNA, mRNA with polyA tail was enriched by Oligo (dT) magnetic beads, and the resulting mRNA was randomly disrupted with divalent cations in Fragmentation Buffer. The first strand of cDNA is synthesized in M-MuLV reverse transcriptase system with fragmented mRNA as template and random oligonucleotide as primer, and then RNA strand is degraded with RNaseH, and the second strand of cDNA is synthesized with dNTPs as material in DNA polymerase I system. The purified double-stranded cDNA is subjected to end repair, A tail addition and sequencing joint connection, cDNA about 370-420 bp is screened by using AMPure XP beads, PCR amplification is carried out, and the PCR product is purified again by using the AMPure XP beads, so that a library is finally obtained. After the library construction was completed, initial quantification was performed using a qubit2.0 Fluorometer, the library was diluted to 1.5ng/ul, then the library was examined for insert size using an Agilent 2100bioanalyzer, and after insert size was expected, qRT-PCR was performed to accurately quantify the effective concentration of the library (library effective concentration was higher than 2 nM) to ensure library quality.
3. Sequencing on a machine: after library qualification, the different libraries were sequenced with Illumina NovaSeq 6000 after pooling according to the effective concentration and demand for target off-press data volume, and a 150bp paired-end reading was generated. The basic principle of sequencing is sequencing-by-synthesis (Sequencing by Synthesis). Four fluorescence-labeled dNTPs, DNA polymerase and a linker primer are added into a sequenced flow cell for amplification, when each sequencing cluster extends a complementary strand, each fluorescence-labeled dNTP is added to release corresponding fluorescence, and a sequencer captures a fluorescence signal and converts the optical signal into a sequencing peak through computer software, so that sequence information of a fragment to be detected is obtained.
2. Data analysis
1. Data quality control
2. Sequence alignment to a reference genome
3. Quantification of Gene expression levels
4. Differential expression analysis
5. Differential gene enrichment analysis
Results of Gene analysis
The experimental group was compared with the control group to obtain 312 expression difference genes, wherein 233 genes were up-regulated and 79 genes were down-regulated (compared with the existing database, fig. 4). Expression associated with cell proliferationThe up-regulation is respectively as follows: DP-1,2, smad2,3,4, SCF, kip1,2, rb, P300, DNA-PK, ATMATR, PCNA, smc1, stag1,2, rad21, mps1, mad2, bubR1, bub3, APC/C, 14-3-3, cycH, CDK7, CDK1, cycB, CDK1, SCF, P107, 130, rb, ab1, HDAC, DP-1,2, ORC, dbf4, CDK1, rb, cycB; genes whose expression is down-regulated include E 2 F 4,5 、C-Myc、Miz1、Skp2、Cip1、P53、14-3-3σ、CDK4,6、CycA、Skp2、MCM、Wee、Cdh1、Cdc14。
Test 3:
the preparation is prepared from 10g of Chinese rhubarb (bag decoction), 6g of Chinese white (powdering, swallowing, 2 times daily), 20g of lotus leaf, 10g of phoenix skin, 30g of astragalus root and 15g of glossy privet fruit by taking the basic prescription as a basis, and carrying out clinical intervention for 7 days, decocting with water for 2 times/day or decocting according to the proportion.
14 tongue coating samples are collected before and after administration, 6 healthy control groups collect tongue coating samples according to the requirement. The tongue fur sample collection method comprises the following steps: the oral professional takes a photograph before early morning collection. The sample was scraped with a swab, starting from the middle of the dorsum of the tongue, and scraping 3 times forward from behind, scraping 1cm from the center of the tongue 2 About 5s. Immediately vortex in a MoBio buffer containing 750 ul. The sponge on the swab should be pressed several times, about 20s, against the wall of the centrifuge tube to ensure that bacteria are transferred into the buffer. The buffer was then cryopreserved at-80℃until the experiment was started. The results are shown in the following table:
TABLE 3 comparison of abundance of tongue coating pathogenic bacteria for patients with recurrent oral ulcers before and after administration
| Flora class | Normal control group | Group of canker sores | Ulcer treating decoction group |
| Proteus (Fr.) Kummer | 177043.17±55296 | 201595.60±133919 | 156596.90±119899.47 |
| Bacteroides genus | 148.6±65.85 | 255.67±104.47 | 139.05±173.16 |
| Ciliated fungus | 79895±33241.5 | 90409±57941.70 | 83744.00±78047.89 |
| Neisseria bacterium | 83108.25±24717.32 | 91880.29±88431.34 | 82826.33±61546.11 |
Note that: p <0.05vs. oral mucosa erosive tongue coating colony-associated Proteus, bacteroides, ciliates and Neisseria in normal control group. It was verified that the main causative factor of pathogenic microorganisms is due to an increase in the proportion of pathogenic bacteria.
TABLE 4 comparison of the abundance of recurrent oral ulcer tongue coating beneficial bacteria and short chain fatty acid producing bacteria
| Flora class | Normal control group | Group of canker sores | Ulcer treating decoction group |
| Thick-walled bacteria | 321221.6±49074.20 | 303034.14±139909.70 | 325030.95±81641.60 |
| Faecal coccus | 179±0 | 45.5±13.44 | 113.05±153.96 |
| Eubacterium (SCFAS-producing bacteria) | 399.10±564.59 | 164.46±111.30 | - |
| Clostridium (SCFAs-producing bacteria) | 2360.96±2581.75 | 1711.16±1633.10 | - |
| Vibrio (SCFAs producing bacteria) | 1172.32±952.24 | 749.99±619.93 | - |
Note that: p <0.05vs. normal control group.
The metabonomics component analysis of the ulcer healing decoction formula: estradiol, butyric acid, berberine, acetoacetic acid, toluic acid, aminopentanoic acid, pyruvic acid, phloroglucinol, oxycodone, norepinephrine, ornithine, lysine, methionine, glutamic acid, mirtazapine, tryptophan, lysine, epinephrine, isovaleric acid, glutathione, aminobutyric acid, glucoside, and the like.
The research shows that after the ulcer healing soup intervenes in the erosion of the oral mucosa, the phenomenon that the beneficial bacteria are quickly recovered from the tongue coating of the patient occurs. Butyric acid is critical to maintaining the integrity of the tight junctions between intestinal epithelial cells. The literature research shows that butyric acid is taken as an energy metabolism substrate of cell mitochondria, can promote gene expression and cell proliferation and differentiation, is a main nutrient substance of epithelial cells, provides 70% of total energy for the epithelial cells, and promotes normal cell formation by stabilizing DNA and repairing damage. Animal models of butyrate lavage also showed a significant increase in the number of cells in the stomach wall, density and mucosal thickness. The metabonomics of the invention contains butyric acid, which is important for repairing the erosion of the mucous membrane of the digestive tract. From Table 4, it was found that the number of SCFAs-producing species in patients with oral mucosal erosion was deficient, indicating that the SCFAs-consuming microbiota in the patients was enhanced. Suggesting that there is a significant disorder of SCFAs metabolism, and that the SCFAs metabolic species are associated with mucosal erosion. SCFAs play a key role in mucosal injury, repair and regeneration by maintaining mucosal epithelial cell stability. The disease is a pathological mechanism of mucosal erosion and a curative effect mechanism of curing mucosal erosion by compound traditional Chinese medicine.
The above-described embodiment is only a preferred embodiment of the present invention, and is not limited in any way, and other variations and modifications may be made without departing from the technical aspects set forth in the claims.
Claims (6)
1. The traditional Chinese medicine composition for treating the damage of the digestive tract mucous membrane is characterized by comprising the following raw materials in parts by weight: 25-35 parts of astragalus membranaceus, 16-23 parts of cotton rose hibiscus leaves, 12-18 parts of glossy privet fruits, 8-12 parts of Chinese yolks, 8-12 parts of phoenix membranes and 5-8 parts of Chinese white; the traditional Chinese medicine composition is prepared into tablets, capsules, aqua, suppositories or powder.
2. The traditional Chinese medicine composition for treating the damage to the mucous membrane of the digestive tract according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 30 parts of astragalus membranaceus, 20 parts of cotton rose hibiscus leaves, 15 parts of glossy privet fruits, 10 parts of human Zhonghuang, 10 parts of phoenix tree skin and 6 parts of human white.
3. The oral spray for curing the ulcers is characterized in that the crude drug content of the oral spray for curing the ulcers is 2-3g/mL, and the crude drug consists of the following components in parts by weight: 25-35 parts of astragalus membranaceus, 16-23 parts of cotton rose hibiscus leaves, 12-18 parts of glossy privet fruits, 8-12 parts of Chinese yolks, 8-12 parts of phoenix membranes and 5-8 parts of Chinese white.
4. The oral spray for curing ulcers according to claim 3, which is characterized in that the preparation method comprises the following steps:
(1) Mixing radix astragali, folium Hibisci Mutabilis, fructus Ligustri Lucidi, human middle-yellow and membrana Follicularis ovi according to formula, soaking in water for 1-2 hr according to the ratio of 1g of medicinal materials to 10-15mL of water, decocting for 3 times to obtain decoction, filtering, concentrating under reduced pressure to obtain primary concentrate containing crude drug 1-1.5g/mL, cooling, adding 95% ethanol of 3 times volume into the primary concentrate, standing overnight, sucking supernatant, recovering ethanol, and concentrating to obtain secondary concentrate containing crude drug 2-3g/m L; adding 95% ethanol 3 times of the volume of the secondary concentrated solution, standing overnight, sucking supernatant, recovering ethanol, and concentrating to obtain tertiary concentrated solution containing crude drug 4-6 g/mL;
weighing Chinese white according to the formula amount, mixing and extracting Chinese white according to the proportion of 1g medicinal material and 8-10mL70-80% ethanol, extracting for 2-3 times at 50-60 ℃ for 1-2 hours each time, filtering, and mixing the extracting solutions;
(2) Filtering the concentrated solution for three times, mixing with the white extractive solution to obtain oral spray with crude drug content of 2-3g/mL for treating ulcer, and packaging.
5. The suppository for curing ulcer is characterized by being prepared by mixing, by weight, 10-20% of medicinal powder and 80-90% of polyoxyethylene stearate, wherein the medicinal powder comprises the following components in parts by weight: 25-35 parts of astragalus membranaceus, 16-23 parts of cotton rose hibiscus leaves, 12-18 parts of glossy privet fruits, 8-12 parts of Chinese yolks, 8-12 parts of phoenix membranes and 5-8 parts of Chinese white.
6. The suppository of claim 5, wherein the powder is prepared by mixing radix astragali, folium Hibisci Mutabilis, fructus Ligustri Lucidi, homo-yellow, membrana Follicularis ovi and homo-white, micronizing, and sieving.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211156848.4A CN115463172B (en) | 2022-09-21 | 2022-09-21 | Traditional Chinese medicine composition for treating digestive tract mucous membrane injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211156848.4A CN115463172B (en) | 2022-09-21 | 2022-09-21 | Traditional Chinese medicine composition for treating digestive tract mucous membrane injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115463172A CN115463172A (en) | 2022-12-13 |
| CN115463172B true CN115463172B (en) | 2024-02-13 |
Family
ID=84335468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211156848.4A Active CN115463172B (en) | 2022-09-21 | 2022-09-21 | Traditional Chinese medicine composition for treating digestive tract mucous membrane injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115463172B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476885A (en) * | 2003-06-10 | 2004-02-25 | 王印雄 | Nianmoyankuiling for curing mucositis mucitis and its preparation |
| CN106361993A (en) * | 2016-10-25 | 2017-02-01 | 陕西中医药大学 | Medicinal composition for preventing and treating gastric mucosal lesion and preparation method of medicinal composition |
| CN107982470A (en) * | 2017-10-31 | 2018-05-04 | 四川兴聚焦医药科技有限责任公司 | A kind of pill medicine for treating canker sore and preparation method thereof |
| CN110772598A (en) * | 2019-11-10 | 2020-02-11 | 肖淑珍 | Composition for treating aphtha, application and taking method thereof |
-
2022
- 2022-09-21 CN CN202211156848.4A patent/CN115463172B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476885A (en) * | 2003-06-10 | 2004-02-25 | 王印雄 | Nianmoyankuiling for curing mucositis mucitis and its preparation |
| CN106361993A (en) * | 2016-10-25 | 2017-02-01 | 陕西中医药大学 | Medicinal composition for preventing and treating gastric mucosal lesion and preparation method of medicinal composition |
| CN107982470A (en) * | 2017-10-31 | 2018-05-04 | 四川兴聚焦医药科技有限责任公司 | A kind of pill medicine for treating canker sore and preparation method thereof |
| CN110772598A (en) * | 2019-11-10 | 2020-02-11 | 肖淑珍 | Composition for treating aphtha, application and taking method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 《中国粪便类药物及其临床应用》;时小红;《中华中医药杂志》;第第32卷卷(第第8期期);3417-3420页 * |
| 《贞芪扶正胶囊治疗复发性口腔溃疡患者疗效观察》;王晓昆;《现代中西医结合杂志》;第第29卷卷(第第28期期);3163-3166,3167 * |
| 贞芪扶正冲剂对慢性萎缩性胃炎的疗效(胃镜及活检病理对比观察);苏继忠;兰州医学院学报;-;第18卷(第02期);1-2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115463172A (en) | 2022-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115463172B (en) | Traditional Chinese medicine composition for treating digestive tract mucous membrane injury | |
| CN117815262A (en) | Application of herba Sonchi arvensis polysaccharide extract in preventing and treating ulcerative colitis | |
| CN117899133A (en) | Application of flavonoid extract of herba Sonchi arvensis in preventing and treating ulcerative colitis | |
| CN106822227B (en) | Preparation method of traditional Chinese medicine Renzhonghuang | |
| CN115487280B (en) | Traditional Chinese medicine composition for dispelling effects of alcohol, protecting liver and promoting liver regeneration as well as preparation and preparation method thereof | |
| CN111686202A (en) | Compound traditional Chinese medicine composition for inhibiting inflammatory progression of active ulcerative colitis and preparation method and application thereof | |
| CN113143996B (en) | Application of mulberry extract in preparation of composition for treating intestinal inflammation of animals | |
| CN110538280A (en) | antidepressant confirmed by pharmacological activity and preparation method thereof | |
| CN116370596B (en) | A Chinese medicinal composition for treating biliary tract diseases | |
| CN115177694B (en) | Plant composite extract and preparation method and application thereof | |
| CN115814049B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN114767810B (en) | Traditional Chinese medicine composition for treating acute lung injury as well as preparation method and application thereof | |
| CN113599414B (en) | Application of diaphragma juglandis aqueous extract in preparation of medicine for treating ulcerative colitis | |
| CN104887967A (en) | Traditional Chinese medicine composition for treating ulcerative colitis and preparation method thereof | |
| CN109771480B (en) | Traditional Chinese medicine composition for treating livestock and poultry hepatotoxicity and preparation method and preparation thereof | |
| CN117982528A (en) | Application of schisandra chinensis polysaccharide in preparation of medicines for relieving DSS-induced ulcerative colitis of mice | |
| CN116159094A (en) | Pharmaceutical composition for preventing or treating pancreatic cancer and kit for detecting pancreatic cancer | |
| CN107383121B (en) | Preparation method of 3, 4-dihydroxy phenylethanoid glycoside and application thereof in preparation of medicine for treating ulcerative colitis | |
| CN117100761A (en) | Application of mangostin in preparing medicine for preventing or treating inflammatory bowel disease | |
| Luo et al. | Banxia Xiexin decoction modulates gut microbiota and gut microbiota metabolism to alleviate DSS-induced ulcerative colitis | |
| CN115040606A (en) | Application of polygonatum odoratum extract in preparation of medicines for treating inflammatory bowel diseases | |
| CN118078942A (en) | Composition and granule preparation for treating obstructive sleep apnea-hypopnea syndrome and preparation method thereof | |
| CN116098934A (en) | Functional herba Schizonepetae extract and its application in relieving colitis and regulating intestinal flora | |
| Mahdizadehdehosta et al. | Comparative study of anti-diabetic effects of insulin, epigenin and Salvia mirzayanii extract in streptozotocin-induced diabetic male rats | |
| CN116672382A (en) | Traditional Chinese medicine composition for treating liver fibrosis and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |